Toll-like receptors and prostate cancer

88Citations
Citations of this article
116Readers
Mendeley users who have this article in their library.

Abstract

Prostate cancer is the second leading cause of cancer-related death in men after lung cancer. Immune responses clearly play a critical role in the tumorigenesis and in the efficacy of radiation therapy and chemotherapy in prostate cancer; however, the underlying molecular mechanisms are still poorly understood. Toll-like receptors (TLRs) are a well-known family of pattern recognition receptors that play a key role in host immune system. Recent studies demonstrate that there are links between TLRs and cancer; however, the function and biological importance of TLRs in prostate cancer seems complex. To elucidate the role of TLRs and innate immunity in prostate cancer might provide us with a better understanding of the molecular mechanisms of this disease. Moreover, utilizing the agonists or antagonists of TLRs might represent a promising new strategy against prostate cancer. In this review, we summarize recent advances on the studies of association between TLR signaling and prostate cancer, TLR polymorphisms and prostate cancer risk, and provide some insights about TLRs as potential targets for prostate cancer immunotherapy. © 2014 Zhao, Zhang, Zhang, Wang and Zhang.

Cite

CITATION STYLE

APA

Zhao, S., Zhang, Y., Zhang, Q., Wang, F., & Zhang, D. (2014). Toll-like receptors and prostate cancer. Frontiers in Immunology. Frontiers Research Foundation. https://doi.org/10.3389/fimmu.2014.00352

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free